Adam Edwards

Adam Edwards is an Adjunct Senior Research Fellow at the Centre for Neuromuscular and Neurological Disorders (Perron Institute) within the UWA Medical School at The University of Western Australia. His research focuses on neuroprotective agents, particularly cationic arginine-rich peptides (CARPs), with significant contributions to understanding their therapeutic potential for neurological conditions.

Dr. Edwards' research expertise spans multiple critical areas in neuroscience and pharmacology:

• Neuroprotective mechanisms against excitotoxicity and cerebral ischemia
• Polyarginine peptide stability and safety profiles
• Applications in stroke models and neonatal brain injury
• Therapeutic development of cationic arginine-rich peptides
• Clinical translation of peptide-based neuroprotectants

His publication record shows a clear progression from basic safety assessments to complex in vivo models, with recent work expanding into neonatal applications. The research demonstrates consistent focus on poly-arginine peptides (particularly R18 and R18D variants), examining their proteolytic stability, safety profiles, and efficacy in models of cerebral ischemia and neuroprotection.

Dr. Edwards is actively accepting PhD and other Higher Degree by Research Students, indicating ongoing mentorship responsibilities. His work has garnered significant attention with an h-index of 11 and 406 citations according to Scopus metrics, reflecting substantial impact in the neuroprotection field.

His primary research activities occur at the Centre for Neuromuscular and Neurological Disorders (Perron Institute), where he collaborates with multidisciplinary teams spanning neuroscience, pharmacology, and clinical medicine to advance peptide-based therapeutic approaches for neurological disorders.